Prostaglandin Synthase: Potential Drug Target Or Biomarker (P47633)

Target Name: Prostaglandin synthase

NCBI ID: P47633

Prostaglandin synthase

Other Name(s): PTGS

Prostaglandin Synthase: Potential Drug Target Or Biomarker

Prostaglandin synthase (nonspecific subtype) (PTGS) is an enzyme that plays a crucial role in the production of prostaglandins, which are naturally occurring compounds that regulate various physiological processes in the body. PTGS is a key enzyme in the production of prostaglandins, and its function is highly sought after as a potential drug target or biomarker.

Prostaglandins are small signaling molecules that help regulate various physiological processes, including inflammation, pain, and blood pressure. They are produced by the body's tissues and are responsible for signaling the presence of certain types of damage or inflammation. PTGS is the enzyme that ultimately produces the prostaglandins.

PTGS is a highly conserved enzyme that is found in most tissues throughout the body. It is a key enzyme in the production of prostaglandins, which are synthesized from arachidonic acid. Arachidonic acid is a fatty acid that is derived from the breakdown of certain foods, such as meat and dairy products. It is also a precursor to the production of certain hormones, including testosterone and estrogen.

PTGS is a transmembrane protein that is located on the surface of cells. It is a member of the A protein family, which is characterized by the presence of a transmembrane region and a cytoplasmic tail. PTGS is involved in the production of prostaglandins by catalyzing the synthesis of the 20-carbon precursor, arachidonic acid, from the more basic precursor, 11-hydroxy-arachidonic acid.

The production of prostaglandins by PTGS is highly regulated. One of the key mechanisms that regulate this process is the production of specific inhibitors, known as agonists, which bind to and inhibit the activity of PTGS. These inhibitors help to reduce the amount of prostaglandins that are produced by the enzyme.

PTGS is also a target for certain drugs that are used to treat various diseases, including cardiovascular disease and inflammatory conditions. For example, a class of drugs called 5-lipoxygenase (5-LO) inhibitors are commonly used to treat inflammatory conditions, such as heart failure and rheumatoid arthritis. These drugs work by inhibiting the activity of 5-LO, which is an enzyme that is produced by PTGS.

In addition to its potential as a drug target, PTGS is also a potential biomarker for certain diseases. The production of prostaglandins by PTGS is often abnormal in many diseases, including cardiovascular disease and inflammatory conditions. Therefore, the levels of prostaglandins produced by PTGS may be a useful biomarker for these diseases.

In conclusion, Prostaglandin synthase (nonspecific subtype) (PTGS) is a highly conserved enzyme that is involved in the production of prostaglandins. It is a key enzyme in the production of these small signaling molecules, and its function is highly sought after as a potential drug target or biomarker. Further research is needed to fully understand the role of PTGS in the production of prostaglandins and its potential as a drug target or biomarker.

Protein Name: Prostaglandin Synthase (nonspecified Subtype)

The "Prostaglandin synthase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Prostaglandin synthase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets